gg. If the FDA took a very conservative position such as approving only secondary prevention diabetics with TG’s over 150 and LDL under 100 ... on optimal statin therapy ... on label .... where would you value AMRN ?
I can see a variety of scenario’s ... from the most conservative above to the most liberal ...being as an add on for anyone on statin therapy